{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:56:37Z","timestamp":1793058997854,"version":"4.5.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Daiichi Sankyo, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trastuzumab deruxtecan (T-DXd), an approved human epidermal growth factor receptor 2 (HER2)-directed antibody\u2013drug conjugate, may cause treatment-emergent adverse events (TEAEs), most commonly gastrointestinal and hematologic TEAEs. This pooled analysis evaluated TEAEs across 2 doses of T-DXd in patients with different cancers to support safe and effective real-world use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Data were pooled from 9 phase I-III clinical trials (DS8201-A-J101; DESTINY-Breast01\/02\/03\/04; DESTINY-Lung01\/02; DESTINY-Gastric01\/02) of T-DXd 5.4 or 6.4\u2009mg\/kg every 3\u2009weeks in patients (N\u2009=\u20091678) with metastatic breast, gastric, or lung cancer with varying HER2 expression or HER2 mutation status. Nausea, vomiting, neutropenia, fatigue, and interstitial lung disease (ILD) were evaluated for time to onset and dose-related outcomes. Antiemetic analysis was limited before a 2020 protocol change recommending prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Common TEAEs (in \u226520%) were fatigue, nausea, vomiting, neutropenia, anemia, and thrombocytopenia; mostly grade 1 or 2. TEAEs leading to dose reduction, drug interruption, and discontinuation with T-DXd were 22.6%, 42.8%, and 17.7% (5.4\u2009mg\/kg), and 29.7%, 47.6%, and 16.6% (6.4\u2009mg\/kg), respectively. Neutropenia, nausea, and fatigue occurred in 34.6%, 74.6%, and 56.5% of patients (5.4\u2009mg\/kg) and 49.3%, 65.5%, and 52.8% (6.4\u2009mg\/kg). Adjudicated drug-related ILD occurred in 12.0% and 10.9%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gastrointestinal and hematologic TEAEs were most common, with nausea, neutropenia, and fatigue most commonly reported. ILD\/pneumonitis occurred in \u223c11%-12% of patients, with severe cases infrequent. Most TEAEs were low grade, though dose modifications highlight the need for proactive TEAE management, particularly in older patients and those with renal impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf396","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T13:04:53Z","timestamp":1764335093000},"source":"Crossref","is-referenced-by-count":9,"title":["Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-9212","authenticated-orcid":false,"given":"Yeon Hee","family":"Park","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[{"name":"Oncology Department, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group , Barcelona,","place":["Spain"]},{"name":"IOB Madrid, Institute of Oncology, Hospital Beata Mar\u00eda Ana , Madrid,","place":["Spain"]},{"name":"Oncology Department, Hospital Universitario Torrej\u00f3n, Ribera Group , Madrid,","place":["Spain"]},{"name":"Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid , Madrid,","place":["Spain"]},{"name":"Medica Scientia Innovation Research (MEDSIR) - Oncocl\u00ednicas&Co , Jersey City, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A","family":"Hurvitz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology and Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele and Universit\u00e0 Vita-Salute San Raffaele , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-4718","authenticated-orcid":false,"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[{"name":"Breast Oncology Department, Aichi Cancer Center Hospital , Nagoya,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East , Kashiwa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, Universit\u00e0 degli Studi di Milano, Department of Hematology, Oncology, and Molecular Medicine, Niguarda Cancer Center, and Grande Ospedale Metropolitano Niguarda , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, National Cancer Center Hospital East , Kashiwa,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey Y","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A","family":"Powell","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-3830","authenticated-orcid":false,"given":"Sandra M","family":"Swain","sequence":"additional","affiliation":[{"name":"Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center and Genetic Medicine, MedStar Health , Washington DC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Arunachalam","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Janek","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingkai","family":"Cheng","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changan","family":"Chu","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnima","family":"Verma","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Kuptsova-Clarkson","sequence":"additional","affiliation":[{"name":"Patient Safety, Oncology, AstraZeneca , Gaithersburg, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elton","family":"Mathias","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Goodman","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. , Basking Ridge, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S","family":"Rugo","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center , San Francisco, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"2025122718563306200_oyaf396-B1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2025122718563306200_oyaf396-B2","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025122718563306200_oyaf396-B3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"key":"2025122718563306200_oyaf396-B4","author":"Daiichi Sankyo, Inc","year":"2025"},{"key":"2025122718563306200_oyaf396-B5","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jcph.2295","article-title":"Trastuzumab deruxtecan dosing in human epidermal growth factor receptor 2-positive gastric cancer: population pharmacokinetic modeling and exposure-response analysis","volume":"63","author":"Yoshihara","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"2025122718563306200_oyaf396-B6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025122718563306200_oyaf396-B7","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"2025122718563306200_oyaf396-B8","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"2025122718563306200_oyaf396-B9","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"2025122718563306200_oyaf396-B10","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025122718563306200_oyaf396-B11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"2025122718563306200_oyaf396-B12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025122718563306200_oyaf396-B13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"2025122718563306200_oyaf396-B14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025122718563306200_oyaf396-B15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025122718563306200_oyaf396-B16","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"2025122718563306200_oyaf396-B17","year":"1994"},{"key":"2025122718563306200_oyaf396-B18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.annonc.2025.07.015","article-title":"Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease\/pneumonitis","author":"Rugo","year":"2025","journal-title":"Ann Oncol"},{"key":"2025122718563306200_oyaf396-B19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40264-023-01328-x","article-title":"Clinical guidance on the monitoring and management of trastuzumab deruxtecan (T-DXd)-related adverse events: insights from an Asia-Pacific multidisciplinary panel","volume":"46","author":"Chiu","year":"2023","journal-title":"Drug Saf"},{"key":"2025122718563306200_oyaf396-B20","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12094-024-03383-x","article-title":"Safety profile of trastuzumab deruxtecan in advanced breast cancer: expert opinion on adverse event management","volume":"26","author":"Ciruelos","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"2025122718563306200_oyaf396-B21","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.clbc.2023.09.005","article-title":"Efficacy and safety of trastuzumab deruxtecan in breast cancer: a systematic review and meta-analysis","volume":"23","author":"Dowling","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"2025122718563306200_oyaf396-B22","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/jcpt.13777","article-title":"Safety of trastuzumab deruxtecan: a meta-analysis and pharmacovigilance study","volume":"47","author":"Guo","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2025122718563306200_oyaf396-B23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/jjco\/hyad036","article-title":"The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-expressing solid tumours: a single-arm meta-analysis","volume":"53","author":"Kou","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"2025122718563306200_oyaf396-B24","doi-asserted-by":"crossref","first-page":"104305","DOI":"10.1016\/j.critrevonc.2024.104305","article-title":"Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low\/positive advanced breast cancer: a meta-analysis of randomized controlled trials","volume":"196","author":"Ma","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025122718563306200_oyaf396-B25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1248\/bpb.b23-00695","article-title":"Analysis of adverse events associated with trastuzumab deruxtecan in patients with gastric and breast cancer: a retrospective study","volume":"47","author":"Nonomiya","year":"2024","journal-title":"Biol Pharm Bull"},{"key":"2025122718563306200_oyaf396-B26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12885-022-10015-6","article-title":"Safety and efficacy profile of trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials","volume":"22","author":"Xu","year":"2022","journal-title":"BMC Cancer"},{"key":"2025122718563306200_oyaf396-B27","doi-asserted-by":"crossref","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"2025122718563306200_oyaf396-B28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40264-020-00968-7","article-title":"Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting","volume":"43","author":"Iwasa","year":"2020","journal-title":"Drug Saf"},{"key":"2025122718563306200_oyaf396-B29","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"key":"2025122718563306200_oyaf396-B30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"2025122718563306200_oyaf396-B31","author":"SEER Cancer Stat Facts: Female Breast Cancer. National Cancer Institute"},{"key":"2025122718563306200_oyaf396-B32","author":"SEER Cancer Stat Facts: Stomach Cancer. National Cancer Institute"},{"key":"2025122718563306200_oyaf396-B33","first-page":"e55902","article-title":"Gastric cancer: a comprehensive literature review","volume":"16","author":"Mithany","year":"2024","journal-title":"Cureus"},{"key":"2025122718563306200_oyaf396-B34","author":"Berger"},{"key":"2025122718563306200_oyaf396-B35","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000511049","article-title":"Management of chemotherapy-induced nausea and vomiting with trastuzumab deruxtecan: a case series","volume":"16","author":"Stankowicz","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"2025122718563306200_oyaf396-B36","doi-asserted-by":"crossref","first-page":"100553","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"2025122718563306200_oyaf396-B37","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/cancers14041022","article-title":"Emetogenicity of antibody-drug conjugates (ADCs) in solid tumors with a focus on trastuzumab deruxtecan: insights from an Italian expert panel","volume":"14","author":"Bianchini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025122718563306200_oyaf396-B38","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025122718563306200_oyaf396-B39","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.7150\/jca.87169","article-title":"Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 study","volume":"14","author":"Iihara","year":"2023","journal-title":"J Cancer"},{"key":"2025122718563306200_oyaf396-B40","doi-asserted-by":"crossref","first-page":"1374547","DOI":"10.3389\/fonc.2024.1374547","article-title":"Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice","volume":"14","author":"Notini","year":"2024","journal-title":"Front Oncol"},{"key":"2025122718563306200_oyaf396-B41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s10147-025-02748-8","article-title":"A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced\/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study","volume":"30","author":"Aoyama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"2025122718563306200_oyaf396-B42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.annonc.2024.09.001","article-title":"A randomized, double-blind, placebo-controlled phase. Study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)","volume":"36","author":"Sakai","year":"2025","journal-title":"Ann Oncol"},{"key":"2025122718563306200_oyaf396-B43","author":"Rosenfeld","year":"2024"},{"key":"2025122718563306200_oyaf396-B44","first-page":"P4-05-08","article-title":"Impact of antiemetic prophylaxis on maintaining dose intensity of trastuzumab deruxtecan in HER2-positive advanced breast cancer. Presented at San Antonio Breast. Abstract","volume":"31","author":"Shin","year":"2025","journal-title":"Cancer Symposium"},{"key":"2025122718563306200_oyaf396-B45","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/jpm13111589","article-title":"Speaking of the \"devil\": diagnostic errors in interstitial lung diseases","volume":"13","author":"Arcana","year":"2023","journal-title":"J Pers Med"},{"key":"2025122718563306200_oyaf396-B46","author":"Tsurutani","year":"2024"},{"key":"2025122718563306200_oyaf396-B47","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1470-2045(24)00128-1","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial","volume":"25","author":"Fehm","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025122718563306200_oyaf396-B48","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2023.04.516","article-title":"Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"key":"2025122718563306200_oyaf396-B49","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf048","article-title":"Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician\u2019s choice of chemotherapy in patients with HER2-low mBC","volume":"30","author":"Ueno","year":"2025","journal-title":"The Oncologist"},{"key":"2025122718563306200_oyaf396-B50","doi-asserted-by":"crossref","first-page":"S1100","DOI":"10.1016\/j.annonc.2022.07.1323","article-title":"1205MO updated analysis of DESTINY-Gastric02: a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in Western patients (pts) with HER2-positive (HER2+) unresectable\/metastatic gastric\/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen","volume":"33","author":"Ku","year":"2022","journal-title":"Ann Oncol"},{"key":"2025122718563306200_oyaf396-B51","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC","author":"J\u00e4nne","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2025122718563306200_oyaf396-B52","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"key":"2025122718563306200_oyaf396-B53","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/oncolo\/oyad308","article-title":"Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: the DE-REAL study","volume":"29","author":"Botticelli","year":"2024","journal-title":"Oncologist"},{"key":"2025122718563306200_oyaf396-B54","doi-asserted-by":"crossref","first-page":"101425","DOI":"10.1016\/j.esmoop.2023.101425","article-title":"237P real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): the TREX-Old retrospective registry","volume":"8","author":"Buono","year":"2023","journal-title":"ESMO Open"},{"key":"2025122718563306200_oyaf396-B55","doi-asserted-by":"crossref","first-page":"113954","DOI":"10.1016\/j.ejca.2024.113954","article-title":"Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer: the experience of the Hellenic Cooperative Oncology Group","volume":"200","author":"Fountzilas","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025122718563306200_oyaf396-B56","doi-asserted-by":"crossref","first-page":"e13035","DOI":"10.1200\/JCO.2023.41.16_suppl.e13035","article-title":"Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: a retrospective single institution study","volume":"41","author":"Vosoughi","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf396\/65675401\/oyaf396.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf396\/65675401\/oyaf396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf396\/65675401\/oyaf396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T23:56:43Z","timestamp":1766879803000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf396\/8363224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf396","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,2]]},"article-number":"oyaf396"}}